Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143077 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
A Phase 3 study of Schizophrenia and Schizoaffective Disorder, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 244
- Enrollment target
- 20
- Study locations
NCT01143077 is a Phase 3 study of Schizophrenia and Schizoaffective Disorder that has completed, run by Sumitomo Pharma America. The registered enrollment target is 244 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT01143077, a Phase 3 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 244 participants
- Enrollment target
- 20
- Study locations
Study Summary
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.
Conditions Studied
Interventions
- DRUG Lurasidone HCl
Study Locations (20)
California
- Synergy Clinical Research of Escondido - Escondido
- Collaborative Neuroscience Network, Inc. - Garden Grove
- Pacific Research Partners, LLC - Oakland
- California Clinical Trials - Paramount
- Pasadena Research Institute - Pasadena
- California Neuropsychopharmacology Clinical Research Institute (CNRI), LLC - Pico Rivera
- California Neuropsychopharmacology Clinical Research Institute (CNRI) - San Diego
- University of California San Diego Medical Center - San Diego
- Collaborative Neuroscience Network, South Bay - Torrance
Georgia
- Comprehensive NeuroScience, Inc. - Atlanta
- Medical College of Georgia - Augusta
New York
- Neurobehavioral Research, Inc. - Cedarhurst
- The Zucker Hillside Hospital - Glen Oaks
North Carolina
- Duke University Dept. of Psychiatry - Durham
- Wake Forest University Health Sciences - Winston-Salem
Arkansas
- K and S Professional Research Services - Little Rock
Colorado
- Western Affiliated Research Institute - Denver
Illinois
- University of Illinois at Chicago - Chicago
Louisiana
- Lake Charles Clinical Trials, LLC - Lake Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01143077
The ClinicalTrials.gov registry entry for NCT01143077 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (12% higher). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Lurasidone HCl is the first listed.
NCT01143077 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT01143077 about?
NCT01143077 is a clinical study titled "A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents". Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effecti...
What is the current status of trial NCT01143077?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 244 participants. The study started on 2010-06. Estimated completion is 2011-05.
What conditions does trial NCT01143077 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT01143077?
The interventions under investigation include: Lurasidone HCl (DRUG).
Who is sponsoring clinical trial NCT01143077?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01143077 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.